



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PIGF (m): 293T Lysate: sc-122646

BACKGROUND

The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF). Like VEGF, several PIGF variants have been shown to arise from alternative mRNA splicings. Evidence has suggested VEGF to be an obligatory component in PIGF signaling. While VEGF homodimers and VEGF/PIGF heterodimers function as potent mediators of mitogenic and chemotactic responses in endothelial cells, PIGF homodimers are effectual only at extremely high concentrations. Indeed, many of the physiological effects attributed to VEGF may actually be a result of VEGF/PIGF. VEGF and PIGF share a common receptor, Flt-1, and may also activate Flk-1/KDR.

REFERENCES

1. Folkman, J. and Klagsbrun, M. 1987. Angiogenic factors. *Science* 235: 442-447.
2. Folkman, J., Watson, K., Ingber, D. and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 339: 58-61.
3. Bouck, N. 1990. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. *Cancer Cells* 2: 179-185.
4. Ferrara, N., Houck, K.A., Jakeman, L.B., Winer, J. and Leung, D.W. 1991. The vascular endothelial growth factor family of polypeptides. *J. Cell. Biochem.* 47: 211-218.
5. DiSalvo, J., Bayne, M.L., Conn, G., Kwok, P.W., Tivedi, P.G., Soderman, D.D., Palisi, T.M., Sullivan, K.A. and Thomas, K.A. 1995. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. *J. Biol. Chem.* 270: 7717-7723.
6. Cao, Y., Chen, H., Zhou, L., Chiang, M.K., Anand-Apte, B., Weatherbee, J.A., Wang, Y., Fang, F., Flanagan, J.G. and Tsang, M.L. 1996. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression and high affinity binding to Flk-1/KDR. *J. Biol. Chem.* 271: 3154-3162.
7. Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J. and Risau, W. 1996. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for functional role of placenta growth factor in monocyte activation and chemotaxis. *J. Biol. Chem.* 271: 17629-17634.

CHROMOSOMAL LOCATION

Genetic locus: Pgf (mouse) mapping to 12 D2.

PRODUCT

PIGF (m): 293T Lysate represents a lysate of mouse PIGF transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

PIGF (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive PIGF antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.